Vaxcyte
PCVX
78 hedge funds and large institutions have $1.1B invested in Vaxcyte in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 29 increasing their positions, 26 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
13% more capital invested
Capital invested by funds: $973M → $1.1B (+$123M)
12% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 26
4% more funds holding
Funds holding: 75 → 78 (+3)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
1.37% less ownership
Funds ownership: 84.15% → 82.77% (-1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.73M |
| 2 |
BlackRock
New York
|
+$4.32M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$3.88M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.95M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$8.9M |
| 2 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
-$7.37M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$3.71M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$1.58M |
| 5 |
Citigroup
New York
|
-$1.45M |
PCVX Hedge Fund Activity: Q3 2021 in Review
78 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q3 2021, worth a combined $1.1B — up 13% from $973M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new PCVX positions and 5 closed out — a net gain of 3 holders — while 29 added to existing stakes and 26 trimmed.
The largest buyer was Vanguard Group, adding an estimated $4.73M. The largest seller was State Street, cutting an estimated $8.9M.
- 78 institutional investors held Vaxcyte (PCVX) as of Q3 2021, up from 75 in Q2 2021.
- Funds reported $1.1B of Vaxcyte stock for Q3 2021, up 13% quarter-over-quarter.
- 8 funds opened new Vaxcyte positions in Q3 2021 and 5 closed out, a net change of +3 holders.
- The largest Vaxcyte buyer in Q3 2021 was Vanguard Group, an estimated $4.73M added.
- The largest Vaxcyte seller in Q3 2021 was State Street, an estimated $8.9M sold.
Based on aggregated 13F filings for Q3 2021.